Options for advanced systemic prostate cancer with the aim to achieve castrate-levels of testosterone include bilateral orchiectomy (surgical castration), luteinizing hormone receptor analogs with or without complete androgen blockade, androgen receptor (AR) antagonists (steroidal or non-steroidal), and ketoconazole with steroids. The gene discussed is AR; the disease is prostate carcinoma.